ETH Zurich spin-off Enantios secures over CHF 1.8M in Seed funding to innovate complex molecule characterization

01.07.2024

The innovative deeptech company Enantios, originating from ETH Zurich, has successfully raised over CHF 1.8 million in Seed funding. The financial boost will advance its technology, support hiring, and strengthen partnerships, positioning Enantios as a leader in scientific innovation.

VK_400x300256.jpg
Enantios Co-Founders: CTO Roman Wyss and CEO Carin Lightner
Enantios, an ETH Zurich deeptech spin-off announced it raised over 1.8 million CHF for its new molecule characterization method. Enantios technology, developed over a five-year research project at ETH Zurich, enables the complete characterization of complex molecules and aspects of the three-dimensional structure which are not possible to resolve with other methods.

Privilège Ventures led this funding round with additional capital from Zürcher Kantonalbank (ZKB) and several Family Offices and private investors.

Enantios is bringing to market a new innovative approach to molecular characterization which addresses critical bottlenecks in traditional drug development. The company plans to allocate the seed round funding towards several key initiatives, including technology development, talent acquisition, and strategic partnerships with pharmaceutical companies, academic institutions, and research organizations.

Enantios won the second stage of Venture Kick in 2023.

"The support from Venture Kick phase I and II came at a crucial time for our team and company and this early-stage support allowed us to continue moving forward and grow while also hitting key product development milestones," commented Carin Lightner, Co-Founder and CEO of Enantios. "In addition to the financial support, the feedback from the Venture Kick jury in the kickers camps really helped us strengthen our messaging and our resolve to build the best company and product possible".


Enantios Co-Founders: CTO Roman Wyss and CEO Carin Lightner

Additional Links